• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TRxADE Health, Inc. Announces Special Cash Dividend

    7/9/24 8:05:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care
    Get the next $MEDS alert in real time by email

    TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024.

    Forward-Looking Statements

    This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our Company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

    Investor Contact:

    TRxADE Health, Inc.

    6308 Benjamin Rd, Suite 708

    Tampa, Florida 33634

    Email: [email protected]



    Primary Logo

    Get the next $MEDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDS

    DatePrice TargetRatingAnalyst
    12/9/2021$4.50Buy
    EF Hutton
    More analyst ratings

    $MEDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Shankar Hariharan claimed ownership of 97,087 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:01 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • New insider Narasimhan Mani claimed ownership of 57,977 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:00 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Ajjarapu Surendra K was granted 10,000 shares (SEC Form 4) (Amendment)

      4/A - TRxADE HEALTH, INC (0001382574) (Issuer)

      5/28/24 5:01:21 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Trxade Health with a new price target

      EF Hutton initiated coverage of Trxade Health with a rating of Buy and set a new price target of $4.50

      12/9/21 9:10:50 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Maxim Group initiated coverage on Trxade Group

      Maxim Group initiated coverage of Trxade Group with a rating of Buy

      2/26/21 8:08:35 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    SEC Filings

    See more
    • TRxADE HEALTH Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Scienture Holdings, Inc. (0001382574) (Filer)

      9/24/24 4:05:38 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form DEF 14C filed by TRxADE HEALTH Inc.

      DEF 14C - TRxADE HEALTH, INC (0001382574) (Filer)

      8/28/24 4:05:30 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form PRE 14C filed by TRxADE HEALTH Inc.

      PRE 14C - TRxADE HEALTH, INC (0001382574) (Filer)

      8/15/24 9:57:20 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care